C
Citryll
Develops therapeutics targeting the neutrophil extracellular trap (NET) pathway to treat inflammatory diseases, with its lead antibody, CIT-013, in clinical trials for rheumatoid arthritis and…
About Citryll
Citryll is a Dutch biotech company focused on developing innovative treatments for autoimmune and other severe diseases such as lupus, vasculitis, pulmonary fibrosis, asthma, rheumatoid arthritis, and organ damage due to sepsis. The company targets the pathobiology of neutrophil extracellular traps (NETs), which are networks of extracellular fibers composed of DNA from neutrophils, a type of white blood cell. By inhibiting the source of autoantigens and NET-derived toxic molecules, Citryll aims to provide a more targeted approach to treatment, avoiding the broad targeting of inflammation or acquired immunity.
Citryll operates in the biopharmaceutical market, primarily serving patients with autoimmune and inflammatory diseases. The company's business model involves the research, development, and commercialization of therapeutic antibodies. Citryll makes money through the development and eventual sale of its proprietary treatments, as well as potential partnerships and licensing agreements with larger pharmaceutical companies.
Citryll's lead product, CIT-013, is currently in the development phase, with first human dosing planned as part of a Single Ascending Dose (SAD) study in healthy volunteers. The company collaborates with partners like Lonza for GMP production and formulation of the antibody.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Oss, Netherlands
- Employees
- 39
- Open positions
- None listed
- Dealroom signal
- 87.6/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Neurology, Autoimmune, Inflammatory Diseases, Biotech and Pharma, Seal of Excellence EC, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Dec 2024 | $94M | $374M | BioGeneration Ventures · BOM - Brabant Regional Development Agency · Pureos Bioventures · Curie Capital | ↗ |
| EARLY VCOther financing | Jul 2020 | $20M | $81M | BrightGene · Seventure Partners · BioGeneration Ventures · BOM - Brabant Regional Development Agency | — |
Growth signals
Latest recorded traffic for Citryll is 1.4K monthly website visits, up 0% over the last three months. Citryll's team grew 21.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A10 investors entered at this stage
BOM - Brabant Regional Development Agency
ModiQuest
BrightGene
Seventure Partners
BioGeneration Ventures
Johnson & Johnson Innovation
Novartis Venture Fund
Forbion Capital Partners
Pureos Bioventures
Curie Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Citryll on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Citryll’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.